Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer

Cancers

卷:14

Charlotte De Bondt¹  Charlotte Billiet²  Toon Allaeys³  Patrick Lauwers³  Suresh Krishan Yogeswaran³  Lawek Berzenji³  Jeroen M. H. Hendriks³  Paul E. Van Schil³ 

[1] Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium;

[2] Department of Radiation Oncology, Iridium Network, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium;

[3] Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium;

关键词: non-small cell lung cancer;    chemotherapy;    radiotherapy;    chemoradiotherapy;    concomitant;    locally advanced;   

DOI  :  10.3390/cancers14071656

来源: DOAJ

【 摘 要 】

For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.

【 授权许可】

Unknown